Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts.
Elevated cardiac levels of nitric oxide (NO) generated by inducible nitric oxide synthase (iNOS) have been implicated in the development of heart failure. The surprisingly benign phenotype of recently generated mice with cardiac-specific iNOS overexpression (TGiNOS) provided the rationale to investigate whether NO scavenging by oxymyoglobin (MbO2) yielding nitrate and metmyoglobin (metMb) is involved in preservation of myocardial function in TGiNOS mice. 1H nuclear magnetic resonance (NMR) spectroscopy was used to monitor changes of cardiac myoglobin (Mb) metabolism in isolated hearts of wild-type (WT) and TGiNOS mice. NO formation by iNOS resulted in a significant decrease of the MbO2 signal and a concomitantly emerging metMb signal in spectra of TGiNOS hearts only (DeltaMbO2: -46.3+/-38.4 micromol/kg, DeltametMb: +41.4+/-17.6 micromol/kg, n=6; P<0.05) leaving contractility and energetics unaffected. Inhibition of the Mb-mediated NO degradation by carbon monoxide (20%) led to a deterioration of myocardial contractility in TGiNOS hearts (left ventricular developed pressure: 78.2+/-8.2% versus 96.7+/-4.6% of baseline, n=6; P<0.005), which was associated with a profound pertubation of cardiac energy state as assessed by 31P NMR spectroscopy (eg, phosphocreatine: 13.3+/-1.3 mmol/L (TGiNOS) versus 15.9+/-0.7 mmol/L (WT), n=6; P<0.005). These alterations could be fully antagonized by the NOS inhibitor S-ethylisothiourea. Our findings demonstrate that myoglobin serves as an important cytoplasmic buffer of iNOS-derived NO, which determines the functional consequences of iNOS overexpression.
Wunderlich
Carsten
C
Institute for Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany.
Flögel
Ulrich
U
Gödecke
Axel
A
Heger
Jacqueline
J
Schrader
Jürgen
J
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D002245:Carbon Dioxide / Q000494:pharmacology; D002248:Carbon Monoxide / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005838:Genotype; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D007550:Isothiuronium / Q000031:analogs & derivatives* / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008786:Metmyoglobin / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D009211:Myoglobin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009566:Nitrates / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D009573:Nitrites / Q000378:metabolism; D009584:Nitrogen / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology; D010477:Perfusion / Q000379:methods; D010725:Phosphocreatine / Q000378:metabolism; D017725:Ventricular Pressure / Q000187:drug effects
D004791:Enzyme Inhibitors; D009211:Myoglobin; D009566:Nitrates; D009573:Nitrites; C018013:carboxymyoglobin; C017595:oxymyoglobin; D010725:Phosphocreatine; D008786:Metmyoglobin; D002245:Carbon Dioxide; D007550:Isothiuronium; C007687:etiron; D002248:Carbon Monoxide; C011700:carbogen; D000255:Adenosine Triphosphate; D001120:Arginine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D009584:Nitrogen; D010100:Oxygen